Joseph W Kim
Yale University · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph W Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06100705 · Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCYale University · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT03047213 · Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsNational Cancer Institute (NCI) · active not recruiting · Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma · principal investigator
- Ph2NCT02893917 · Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerNational Cancer Institute (NCI) · active not recruiting · Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation · principal investigator
- Ph2NCT02498613 · A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA016359 · NCI · YALE UNIVERSITY · fiscal years 2025 to 2026 · $231,156 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT02498613
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:40 UTC. The ranking covers the 200 most relevant of 447 PubMed records, and a shared surname and initials can bring in a namesake. All 447 on PubMed
- 1,094 citationsRCR 78.5
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.N Engl J Med · 2019435 citationsRCR 18.6
- 370 citationsRCR 21.4
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol · 2024300 citationsRCR 38.0
- Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.Lancet Gastroenterol Hepatol · 2022287 citationsRCR 19.5
- Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.N Engl J Med · 2021283 citationsRCR 17.2
- 269 citationsRCR 11.0
- Incorporation of pazopanib in maintenance therapy of ovarian cancer.J Clin Oncol · 2014250 citationsRCR 7.4
- Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.Lancet Oncol · 2023248 citationsRCR 20.9
- Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.N Engl J Med · 2019247 citationsRCR 10.4